Additionally, the 36-month beta value for BIOR is 1.25. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIOR is 33.83M and currently, short sellers hold a 5.94% ratio of that float. The average trading volume of BIOR on September 20, 2024 was 192.34K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BIOR) stock’s latest price update
Biora Therapeutics Inc (NASDAQ: BIOR)’s stock price has gone decline by -7.65 in comparison to its previous close of 0.65, however, the company has experienced a -7.69% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-08-26 that SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the H.C. Wainwright 26th Annual Global Investment Conference, September 9–11, 2024.
BIOR’s Market Performance
Biora Therapeutics Inc (BIOR) has seen a -7.69% fall in stock performance for the week, with a -13.17% decline in the past month and a -11.75% plunge in the past quarter. The volatility ratio for the week is 4.66%, and the volatility levels for the past 30 days are at 4.60% for BIOR. The simple moving average for the last 20 days is -9.66% for BIOR’s stock, with a simple moving average of -29.81% for the last 200 days.
BIOR Trading at -9.61% from the 50-Day Moving Average
After a stumble in the market that brought BIOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.88% of loss for the given period.
Volatility was left at 4.60%, however, over the last 30 days, the volatility rate increased by 4.66%, as shares sank -7.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.79% lower at present.
During the last 5 trading sessions, BIOR fell by -5.88%, which changed the moving average for the period of 200-days by -51.05% in comparison to the 20-day moving average, which settled at $0.6620. In addition, Biora Therapeutics Inc saw -55.55% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIOR
Current profitability levels for the company are sitting at:
- -39.24 for the present operating margin
- 0.74 for the gross margin
The net margin for Biora Therapeutics Inc stands at -49.99. The total capital return value is set at 2.45.
Based on Biora Therapeutics Inc (BIOR), the company’s capital structure generated -1.09 points at debt to capital in total, while cash flow to debt ratio is standing at -1.04. The debt to equity ratio resting at -0.52. The interest coverage ratio of the stock is 24.29.
Currently, EBITDA for the company is -66.59 million with net debt to EBITDA at -0.61. When we switch over and look at the enterprise to sales, we see a ratio of 35.65. The receivables turnover for the company is 2.11for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.20.
Conclusion
In conclusion, Biora Therapeutics Inc (BIOR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
